We have investigated the pathogenesis of various psychiatric diseases. Neuropathology team focused on dementia and identified localization of α-synuclein or FUS protein possibly caused Alzheimer’s disease and FTLD. Recently, Neuroimaging team has been trying to understand brain structural deficits in psychiatric diseases using the MRI based measurement with multiple regions of interested and voxel based morphometry. Results have suggested the association of abnormal volume of amygdala with anxiety disorders and the Neuroimaging team continues the study focusing another diseases including schizophrenia.
Secondary, our researches aim the development of psychiatric treatment. Our Neuropharmacology team has been focusing on genetic association with the interindividual differences in drug responses. The team has reported the association between genetic polymorphisms of drug metabolizing enzyme, CYP, and neurotransmitter receptors and both drug efficacy and adverse effects. Besides, our research teams in clinical psychiatry also toward the development of structured rehabilitation program for recovery in schizophrenia, return to work program in mood disorder, and intervention for suicide attempters at critical care units.
1. Asami T et al., Globally and locally reduced MRI gray matter volumes in neuroleptic-naive men with schizotypal personality disorder: association with negative symptoms. JAMA Psychiatry 70, 361-72, 2013
2. Asami T et al., Sexually dimorphic gray matter volume reduction in patients with panic disorder. Psychiatry Res 173, 128-34, 2009
3. Aoki N et al., Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathol 124, 383-94, 2012
4. Chiba Y et al., Anti-glutamate receptor ɛ2 antibodies in psychiatric patients with anti-thyroid autoantibodies--a prevalence study in Japan. Neurosci Lett 534, 217-22, 2013
5. Kishida I et al., Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Mol Psychiatr 9, 293-298, 2004